U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 5881 - 5890 of 6711 results

Group 1 Specified Substance
Status:
Possibly Marketed Outside US

Class:
G1 SPECIFIED SUBSTANCE

Concept
Status:
US Approved Rx (2014)
Source:
BLA125549
(2014)
Source URL:
First approved in 2014
Source:
BLA125549
Source URL:

Class:
CONCEPT

Concept
Status:
US Approved Rx (2014)
Source:
BLA125549
(2014)
Source URL:
First approved in 2014
Source:
BLA125549
Source URL:

Class:
CONCEPT

Concept
Status:
US Approved Rx (2014)
Source:
BLA125549
(2014)
Source URL:
First approved in 2014
Source:
BLA125549
Source URL:

Class:
CONCEPT

Concept
Status:
US Approved Rx (2015)
Source:
BLA125546
(2015)
Source URL:
First approved in 2014
Source:
BLA125549
Source URL:

Class:
CONCEPT

Concept
Status:
Investigational
Source:
NCT03582033: Phase 1 Interventional Terminated Multiple Myeloma
(2018)
Source URL:

Class:
CONCEPT

Showing 5881 - 5890 of 6711 results